Pharmacokinetics and pharmacodynamics integration of danofloxacin against Eschrichia coli in piglet ileum ultrafiltration probe model

被引:0
|
作者
Yuqi Yang
Ping Cheng
Tianshi Xiao
Jargalsaikhan Ulziikhutag
Hongxiao Yu
Jiarui Li
Ruimeng Liu
Ishfaq Muhammad
Xiuying Zhang
机构
[1] University Town,Pharmacology Teaching and Research Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine
[2] Northeast Agricultural University,Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Faculty of Basic Veterinary Science, College of Veterinary Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Improper use of antibiotics results in poor treatment and severe bacterial resistance. In this study, ultrafiltration probes were successfully placed in the ileum of piglets with the aid of anesthetic. After the fluoroquinolone antimicrobial drug danofloxacin (DAN) was intramuscularly administered, blood and ileum ultrafiltrate were collected at different time points and then determined by High Performance Liquid Chromatography (HPLC). Pharmacokinetics (PK) parameters for plasma and ileum ultrafiltrate were calculated by WinNonlin software. The DAN concentration in ileum ultrafiltrate was much higher than that in plasma during the period 1.2–48 h. The DAN concentration in plasma reached its maximum at 1.10 ± 0.03 h, but reached at 6.00 ± 0.00 h in the ileum ultrafiltrate. The mean Cmax of the ileum is 13.59 times that of plasma. The elimination half-life (T1/2β) in the ileum ultrafiltrate (6.84 ± 1.49 h) was shorter than those in plasma (7.58 ± 3.20 h). The MIC, MBC and MPC of DAN in MH broth against Escherichia coli (O158) were 0.5 µg/mL, 0.5 µg/mL and 4 µg/mL, respectively. Both in vitro and ex vivo kill curves indicated that the killing mechanism of DAN against E. coli is concentration-dependent. The AUC/MPC ratio is 21.33 ± 2.14. Mean PK/PD index (AUC24h/MIC) for ileum ultrafiltrate that achieved bacteriostatic, bactericidal, and eradication were 99.85, 155.57, and 218.02 h, respectively. Three different dosages (1.49 mg/kg, 2.42 mg/kg, and 3.24 mg/kg) were calculated respectively based on AUC24h/MIC ratio above, which might provide a novel approach to the rational design of dosage schedules.
引用
收藏
相关论文
共 50 条
  • [31] Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics
    de lange, Elizabeth C. M.
    van den Brink, Willem
    Yamamoto, Yumi
    de Witte, Wilhelmus E. A.
    Wong, Yin Cheong
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (12) : 1207 - 1218
  • [32] Protective immunity of a Multivalent Vaccine Candidate against piglet diarrhea caused by enterotoxigenic Escherichia coli (ETEC) in a pig model
    Zhang, Henghui
    Xu, Yongping
    Zhang, Zhijun
    You, Jiansong
    Yang, Yanyong
    Li, Xiaoyu
    VACCINE, 2018, 36 (05) : 723 - 728
  • [33] Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance
    Lamp, KC
    Vickers, MK
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 231 - 235
  • [34] Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus aureus
    He, Peng
    Li, Xin
    Guo, Xiaohan
    Bian, Xingchen
    Wang, Rui
    Wang, Yue
    Huang, Sijing
    Qi, Mengya
    Liu, Yuanxia
    Feng, Meiqing
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 1019 - 1028
  • [35] In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
    Zhao, Miao
    Lepak, Alexander J.
    VanScoy, Brian
    Bader, Justin C.
    Marchillo, Karen
    Vanhecker, Jamie
    Ambrose, Paul G.
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [36] Integration of pharmacodynamics and metabolomics to reveal rhubarb anthraquinone protection against nonalcoholic fatty liver disease rat model
    Zhang, Fang
    Wu, Rui
    Liu, Yanfang
    Dai, Shu
    Gong, Xiaohong
    Li, Yunxia
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2024, 76 (04) : 381 - 390
  • [37] Pharmacokinetics and Pharmacodynamics of Colistin Combined With Isopropoxy Benzene Guanidine Against mcr-1-Positive Salmonella in an Intestinal Infection Model
    Kong, Lingli
    Lu, Yixing
    Yang, Liuye
    Zhang, Wanying
    Zuo, Beini
    Peng, Xianfeng
    Qin, Zonghua
    Li, Miao
    Zeng, Zhenling
    Zeng, Dongping
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [38] Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
    Banevicius, Mary A.
    Kaplan, Nachum
    Hafkin, Barry
    Nicolau, David P.
    JOURNAL OF CHEMOTHERAPY, 2013, 25 (01) : 26 - 31
  • [39] Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation
    Huang, Chen
    Zheng, Beiwen
    Yu, Wei
    Niu, Tianshui
    Xiao, Tingting
    Zhang, Jing
    Xiao, Yonghong
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 103 - 112
  • [40] Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model
    Lin, Yu-Wei
    Zhou, Qi Tony
    Han, Mei-Ling
    Chen, Ke
    Onufrak, Nikolas J.
    Wang, Jiping
    Turnidge, John D.
    Howden, Benjamin P.
    Forrest, Alan
    Chan, Hak-Kim
    Li, Jian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)